line_item,period,value,symbol
Tax Effect Of Unusual Items,2025-03-31 00:00:00,0.0,ADVENZYMES.NS
Tax Rate For Calcs,2025-03-31 00:00:00,0.284953,ADVENZYMES.NS
Normalized EBITDA,2025-03-31 00:00:00,2274770000.0,ADVENZYMES.NS
Total Unusual Items,2025-03-31 00:00:00,0.0,ADVENZYMES.NS
Total Unusual Items Excluding Goodwill,2025-03-31 00:00:00,0.0,ADVENZYMES.NS
Net Income From Continuing Operation Net Minority Interest,2025-03-31 00:00:00,1311150000.0,ADVENZYMES.NS
Reconciled Depreciation,2025-03-31 00:00:00,365560000.0,ADVENZYMES.NS
Reconciled Cost Of Revenue,2025-03-31 00:00:00,1518610000.0,ADVENZYMES.NS
EBITDA,2025-03-31 00:00:00,2274770000.0,ADVENZYMES.NS
EBIT,2025-03-31 00:00:00,1909210000.0,ADVENZYMES.NS
Net Interest Income,2025-03-31 00:00:00,-35570000.0,ADVENZYMES.NS
Interest Expense,2025-03-31 00:00:00,35570000.0,ADVENZYMES.NS
Interest Income,2025-03-31 00:00:00,,ADVENZYMES.NS
Normalized Income,2025-03-31 00:00:00,1311150000.0,ADVENZYMES.NS
Net Income From Continuing And Discontinued Operation,2025-03-31 00:00:00,1311150000.0,ADVENZYMES.NS
Total Expenses,2025-03-31 00:00:00,4790300000.0,ADVENZYMES.NS
Rent Expense Supplemental,2025-03-31 00:00:00,,ADVENZYMES.NS
Diluted Average Shares,2025-03-31 00:00:00,111872867.0,ADVENZYMES.NS
Basic Average Shares,2025-03-31 00:00:00,111872867.0,ADVENZYMES.NS
Diluted EPS,2025-03-31 00:00:00,11.72,ADVENZYMES.NS
Basic EPS,2025-03-31 00:00:00,11.72,ADVENZYMES.NS
Diluted NI Availto Com Stockholders,2025-03-31 00:00:00,1311150000.0,ADVENZYMES.NS
Net Income Common Stockholders,2025-03-31 00:00:00,1311150000.0,ADVENZYMES.NS
Otherunder Preferred Stock Dividend,2025-03-31 00:00:00,0.0,ADVENZYMES.NS
Net Income,2025-03-31 00:00:00,1311150000.0,ADVENZYMES.NS
Minority Interests,2025-03-31 00:00:00,-28590000.0,ADVENZYMES.NS
Net Income Including Noncontrolling Interests,2025-03-31 00:00:00,1339740000.0,ADVENZYMES.NS
Net Income Continuous Operations,2025-03-31 00:00:00,1339740000.0,ADVENZYMES.NS
Tax Provision,2025-03-31 00:00:00,533900000.0,ADVENZYMES.NS
Pretax Income,2025-03-31 00:00:00,1873640000.0,ADVENZYMES.NS
Other Non Operating Income Expenses,2025-03-31 00:00:00,330410000.0,ADVENZYMES.NS
Special Income Charges,2025-03-31 00:00:00,0.0,ADVENZYMES.NS
Other Special Charges,2025-03-31 00:00:00,,ADVENZYMES.NS
Write Off,2025-03-31 00:00:00,,ADVENZYMES.NS
Impairment Of Capital Assets,2025-03-31 00:00:00,,ADVENZYMES.NS
Net Non Operating Interest Income Expense,2025-03-31 00:00:00,-35570000.0,ADVENZYMES.NS
Total Other Finance Cost,2025-03-31 00:00:00,,ADVENZYMES.NS
Interest Expense Non Operating,2025-03-31 00:00:00,35570000.0,ADVENZYMES.NS
Interest Income Non Operating,2025-03-31 00:00:00,,ADVENZYMES.NS
Operating Income,2025-03-31 00:00:00,1578800000.0,ADVENZYMES.NS
Operating Expense,2025-03-31 00:00:00,3271690000.0,ADVENZYMES.NS
Other Operating Expenses,2025-03-31 00:00:00,1490710000.0,ADVENZYMES.NS
Depreciation And Amortization In Income Statement,2025-03-31 00:00:00,365560000.0,ADVENZYMES.NS
Amortization,2025-03-31 00:00:00,,ADVENZYMES.NS
Depreciation Income Statement,2025-03-31 00:00:00,365560000.0,ADVENZYMES.NS
Research And Development,2025-03-31 00:00:00,,ADVENZYMES.NS
Selling General And Administration,2025-03-31 00:00:00,,ADVENZYMES.NS
Selling And Marketing Expense,2025-03-31 00:00:00,,ADVENZYMES.NS
General And Administrative Expense,2025-03-31 00:00:00,,ADVENZYMES.NS
Rent And Landing Fees,2025-03-31 00:00:00,,ADVENZYMES.NS
Gross Profit,2025-03-31 00:00:00,4850490000.0,ADVENZYMES.NS
Cost Of Revenue,2025-03-31 00:00:00,1518610000.0,ADVENZYMES.NS
Total Revenue,2025-03-31 00:00:00,6369100000.0,ADVENZYMES.NS
Operating Revenue,2025-03-31 00:00:00,6369100000.0,ADVENZYMES.NS
Tax Effect Of Unusual Items,2024-03-31 00:00:00,-40983960.260035,ADVENZYMES.NS
Tax Rate For Calcs,2024-03-31 00:00:00,0.270843,ADVENZYMES.NS
Normalized EBITDA,2024-03-31 00:00:00,2411230000.0,ADVENZYMES.NS
Total Unusual Items,2024-03-31 00:00:00,-151320000.0,ADVENZYMES.NS
Total Unusual Items Excluding Goodwill,2024-03-31 00:00:00,-151320000.0,ADVENZYMES.NS
Net Income From Continuing Operation Net Minority Interest,2024-03-31 00:00:00,1333050000.0,ADVENZYMES.NS
Reconciled Depreciation,2024-03-31 00:00:00,352420000.0,ADVENZYMES.NS
Reconciled Cost Of Revenue,2024-03-31 00:00:00,1445790000.0,ADVENZYMES.NS
EBITDA,2024-03-31 00:00:00,2259910000.0,ADVENZYMES.NS
EBIT,2024-03-31 00:00:00,1907490000.0,ADVENZYMES.NS
Net Interest Income,2024-03-31 00:00:00,-29280000.0,ADVENZYMES.NS
Interest Expense,2024-03-31 00:00:00,29280000.0,ADVENZYMES.NS
Interest Income,2024-03-31 00:00:00,133260000.0,ADVENZYMES.NS
Normalized Income,2024-03-31 00:00:00,1443386039.739965,ADVENZYMES.NS
Net Income From Continuing And Discontinued Operation,2024-03-31 00:00:00,1333050000.0,ADVENZYMES.NS
Total Expenses,2024-03-31 00:00:00,4546510000.0,ADVENZYMES.NS
Rent Expense Supplemental,2024-03-31 00:00:00,79530000.0,ADVENZYMES.NS
Diluted Average Shares,2024-03-31 00:00:00,111833054.0,ADVENZYMES.NS
Basic Average Shares,2024-03-31 00:00:00,111833054.0,ADVENZYMES.NS
Diluted EPS,2024-03-31 00:00:00,11.92,ADVENZYMES.NS
Basic EPS,2024-03-31 00:00:00,11.92,ADVENZYMES.NS
Diluted NI Availto Com Stockholders,2024-03-31 00:00:00,1333050000.0,ADVENZYMES.NS
Net Income Common Stockholders,2024-03-31 00:00:00,1333050000.0,ADVENZYMES.NS
Otherunder Preferred Stock Dividend,2024-03-31 00:00:00,0.0,ADVENZYMES.NS
Net Income,2024-03-31 00:00:00,1333050000.0,ADVENZYMES.NS
Minority Interests,2024-03-31 00:00:00,-36460000.0,ADVENZYMES.NS
Net Income Including Noncontrolling Interests,2024-03-31 00:00:00,1369510000.0,ADVENZYMES.NS
Net Income Continuous Operations,2024-03-31 00:00:00,1369510000.0,ADVENZYMES.NS
Tax Provision,2024-03-31 00:00:00,508700000.0,ADVENZYMES.NS
Pretax Income,2024-03-31 00:00:00,1878210000.0,ADVENZYMES.NS
Other Non Operating Income Expenses,2024-03-31 00:00:00,366640000.0,ADVENZYMES.NS
Special Income Charges,2024-03-31 00:00:00,-151320000.0,ADVENZYMES.NS
Other Special Charges,2024-03-31 00:00:00,154370000.0,ADVENZYMES.NS
Write Off,2024-03-31 00:00:00,20950000.0,ADVENZYMES.NS
Impairment Of Capital Assets,2024-03-31 00:00:00,0.0,ADVENZYMES.NS
Net Non Operating Interest Income Expense,2024-03-31 00:00:00,-29280000.0,ADVENZYMES.NS
Total Other Finance Cost,2024-03-31 00:00:00,11930000.0,ADVENZYMES.NS
Interest Expense Non Operating,2024-03-31 00:00:00,29280000.0,ADVENZYMES.NS
Interest Income Non Operating,2024-03-31 00:00:00,133260000.0,ADVENZYMES.NS
Operating Income,2024-03-31 00:00:00,1692170000.0,ADVENZYMES.NS
Operating Expense,2024-03-31 00:00:00,3100720000.0,ADVENZYMES.NS
Other Operating Expenses,2024-03-31 00:00:00,1470460000.0,ADVENZYMES.NS
Depreciation And Amortization In Income Statement,2024-03-31 00:00:00,352420000.0,ADVENZYMES.NS
Amortization,2024-03-31 00:00:00,77400000.0,ADVENZYMES.NS
Depreciation Income Statement,2024-03-31 00:00:00,352420000.0,ADVENZYMES.NS
Research And Development,2024-03-31 00:00:00,8120000.0,ADVENZYMES.NS
Selling General And Administration,2024-03-31 00:00:00,397220000.0,ADVENZYMES.NS
Selling And Marketing Expense,2024-03-31 00:00:00,156510000.0,ADVENZYMES.NS
General And Administrative Expense,2024-03-31 00:00:00,240710000.0,ADVENZYMES.NS
Rent And Landing Fees,2024-03-31 00:00:00,79530000.0,ADVENZYMES.NS
Gross Profit,2024-03-31 00:00:00,4792890000.0,ADVENZYMES.NS
Cost Of Revenue,2024-03-31 00:00:00,1445790000.0,ADVENZYMES.NS
Total Revenue,2024-03-31 00:00:00,6238680000.0,ADVENZYMES.NS
Operating Revenue,2024-03-31 00:00:00,6238680000.0,ADVENZYMES.NS
Tax Effect Of Unusual Items,2023-03-31 00:00:00,-23816772.801094,ADVENZYMES.NS
Tax Rate For Calcs,2023-03-31 00:00:00,0.26015,ADVENZYMES.NS
Normalized EBITDA,2023-03-31 00:00:00,1869930000.0,ADVENZYMES.NS
Total Unusual Items,2023-03-31 00:00:00,-91550000.0,ADVENZYMES.NS
Total Unusual Items Excluding Goodwill,2023-03-31 00:00:00,-91550000.0,ADVENZYMES.NS
Net Income From Continuing Operation Net Minority Interest,2023-03-31 00:00:00,1056390000.0,ADVENZYMES.NS
Reconciled Depreciation,2023-03-31 00:00:00,350290000.0,ADVENZYMES.NS
Reconciled Cost Of Revenue,2023-03-31 00:00:00,1427680000.0,ADVENZYMES.NS
EBITDA,2023-03-31 00:00:00,1778380000.0,ADVENZYMES.NS
EBIT,2023-03-31 00:00:00,1428090000.0,ADVENZYMES.NS
Net Interest Income,2023-03-31 00:00:00,60050000.0,ADVENZYMES.NS
Interest Expense,2023-03-31 00:00:00,24210000.0,ADVENZYMES.NS
Interest Income,2023-03-31 00:00:00,94830000.0,ADVENZYMES.NS
Normalized Income,2023-03-31 00:00:00,1124123227.198906,ADVENZYMES.NS
Net Income From Continuing And Discontinued Operation,2023-03-31 00:00:00,1056390000.0,ADVENZYMES.NS
Total Expenses,2023-03-31 00:00:00,4020860000.0,ADVENZYMES.NS
Rent Expense Supplemental,2023-03-31 00:00:00,62360000.0,ADVENZYMES.NS
Diluted Average Shares,2023-03-31 00:00:00,111815999.0,ADVENZYMES.NS
Basic Average Shares,2023-03-31 00:00:00,111815999.0,ADVENZYMES.NS
Diluted EPS,2023-03-31 00:00:00,9.45,ADVENZYMES.NS
Basic EPS,2023-03-31 00:00:00,9.45,ADVENZYMES.NS
Diluted NI Availto Com Stockholders,2023-03-31 00:00:00,1056390000.0,ADVENZYMES.NS
Net Income Common Stockholders,2023-03-31 00:00:00,1056390000.0,ADVENZYMES.NS
Otherunder Preferred Stock Dividend,2023-03-31 00:00:00,0.0,ADVENZYMES.NS
Net Income,2023-03-31 00:00:00,1056390000.0,ADVENZYMES.NS
Minority Interests,2023-03-31 00:00:00,17730000.0,ADVENZYMES.NS
Net Income Including Noncontrolling Interests,2023-03-31 00:00:00,1038660000.0,ADVENZYMES.NS
Net Income Continuous Operations,2023-03-31 00:00:00,1038660000.0,ADVENZYMES.NS
Tax Provision,2023-03-31 00:00:00,365220000.0,ADVENZYMES.NS
Pretax Income,2023-03-31 00:00:00,1403880000.0,ADVENZYMES.NS
Other Non Operating Income Expenses,2023-03-31 00:00:00,39400000.0,ADVENZYMES.NS
Special Income Charges,2023-03-31 00:00:00,-64310000.0,ADVENZYMES.NS
Other Special Charges,2023-03-31 00:00:00,48130000.0,ADVENZYMES.NS
Write Off,2023-03-31 00:00:00,9310000.0,ADVENZYMES.NS
Impairment Of Capital Assets,2023-03-31 00:00:00,6870000.0,ADVENZYMES.NS
Net Non Operating Interest Income Expense,2023-03-31 00:00:00,60050000.0,ADVENZYMES.NS
Total Other Finance Cost,2023-03-31 00:00:00,10570000.0,ADVENZYMES.NS
Interest Expense Non Operating,2023-03-31 00:00:00,24210000.0,ADVENZYMES.NS
Interest Income Non Operating,2023-03-31 00:00:00,94830000.0,ADVENZYMES.NS
Operating Income,2023-03-31 00:00:00,1382960000.0,ADVENZYMES.NS
Operating Expense,2023-03-31 00:00:00,2593180000.0,ADVENZYMES.NS
Other Operating Expenses,2023-03-31 00:00:00,752440000.0,ADVENZYMES.NS
Depreciation And Amortization In Income Statement,2023-03-31 00:00:00,350290000.0,ADVENZYMES.NS
Amortization,2023-03-31 00:00:00,73040000.0,ADVENZYMES.NS
Depreciation Income Statement,2023-03-31 00:00:00,277250000.0,ADVENZYMES.NS
Research And Development,2023-03-31 00:00:00,8090000.0,ADVENZYMES.NS
Selling General And Administration,2023-03-31 00:00:00,379080000.0,ADVENZYMES.NS
Selling And Marketing Expense,2023-03-31 00:00:00,160820000.0,ADVENZYMES.NS
General And Administrative Expense,2023-03-31 00:00:00,218260000.0,ADVENZYMES.NS
Rent And Landing Fees,2023-03-31 00:00:00,62360000.0,ADVENZYMES.NS
Gross Profit,2023-03-31 00:00:00,3976140000.0,ADVENZYMES.NS
Cost Of Revenue,2023-03-31 00:00:00,1427680000.0,ADVENZYMES.NS
Total Revenue,2023-03-31 00:00:00,5403820000.0,ADVENZYMES.NS
Operating Revenue,2023-03-31 00:00:00,5403820000.0,ADVENZYMES.NS
Tax Effect Of Unusual Items,2022-03-31 00:00:00,632669.094693,ADVENZYMES.NS
Tax Rate For Calcs,2022-03-31 00:00:00,0.276275,ADVENZYMES.NS
Normalized EBITDA,2022-03-31 00:00:00,2076080000.0,ADVENZYMES.NS
Total Unusual Items,2022-03-31 00:00:00,2290000.0,ADVENZYMES.NS
Total Unusual Items Excluding Goodwill,2022-03-31 00:00:00,2290000.0,ADVENZYMES.NS
Net Income From Continuing Operation Net Minority Interest,2022-03-31 00:00:00,1195820000.0,ADVENZYMES.NS
Reconciled Depreciation,2022-03-31 00:00:00,349830000.0,ADVENZYMES.NS
Reconciled Cost Of Revenue,2022-03-31 00:00:00,1194300000.0,ADVENZYMES.NS
EBITDA,2022-03-31 00:00:00,2078370000.0,ADVENZYMES.NS
EBIT,2022-03-31 00:00:00,1728540000.0,ADVENZYMES.NS
Net Interest Income,2022-03-31 00:00:00,-25510000.0,ADVENZYMES.NS
Interest Expense,2022-03-31 00:00:00,17960000.0,ADVENZYMES.NS
Interest Income,2022-03-31 00:00:00,4040000.0,ADVENZYMES.NS
Normalized Income,2022-03-31 00:00:00,1194162669.094693,ADVENZYMES.NS
Net Income From Continuing And Discontinued Operation,2022-03-31 00:00:00,1195820000.0,ADVENZYMES.NS
Total Expenses,2022-03-31 00:00:00,3603390000.0,ADVENZYMES.NS
Rent Expense Supplemental,2022-03-31 00:00:00,42380000.0,ADVENZYMES.NS
Diluted Average Shares,2022-03-31 00:00:00,111869256.0,ADVENZYMES.NS
Basic Average Shares,2022-03-31 00:00:00,111777150.0,ADVENZYMES.NS
Diluted EPS,2022-03-31 00:00:00,10.68,ADVENZYMES.NS
Basic EPS,2022-03-31 00:00:00,10.7,ADVENZYMES.NS
Diluted NI Availto Com Stockholders,2022-03-31 00:00:00,1195820000.0,ADVENZYMES.NS
Net Income Common Stockholders,2022-03-31 00:00:00,1195820000.0,ADVENZYMES.NS
Otherunder Preferred Stock Dividend,2022-03-31 00:00:00,0.0,ADVENZYMES.NS
Net Income,2022-03-31 00:00:00,1195820000.0,ADVENZYMES.NS
Minority Interests,2022-03-31 00:00:00,-42170000.0,ADVENZYMES.NS
Net Income Including Noncontrolling Interests,2022-03-31 00:00:00,1237990000.0,ADVENZYMES.NS
Net Income Continuous Operations,2022-03-31 00:00:00,1237990000.0,ADVENZYMES.NS
Tax Provision,2022-03-31 00:00:00,472590000.0,ADVENZYMES.NS
Pretax Income,2022-03-31 00:00:00,1710580000.0,ADVENZYMES.NS
Other Non Operating Income Expenses,2022-03-31 00:00:00,45690000.0,ADVENZYMES.NS
Special Income Charges,2022-03-31 00:00:00,2290000.0,ADVENZYMES.NS
Other Special Charges,2022-03-31 00:00:00,-11500000.0,ADVENZYMES.NS
Write Off,2022-03-31 00:00:00,9210000.0,ADVENZYMES.NS
Impairment Of Capital Assets,2022-03-31 00:00:00,0.0,ADVENZYMES.NS
Net Non Operating Interest Income Expense,2022-03-31 00:00:00,-25510000.0,ADVENZYMES.NS
Total Other Finance Cost,2022-03-31 00:00:00,11590000.0,ADVENZYMES.NS
Interest Expense Non Operating,2022-03-31 00:00:00,17960000.0,ADVENZYMES.NS
Interest Income Non Operating,2022-03-31 00:00:00,4040000.0,ADVENZYMES.NS
Operating Income,2022-03-31 00:00:00,1685650000.0,ADVENZYMES.NS
Operating Expense,2022-03-31 00:00:00,2409090000.0,ADVENZYMES.NS
Other Operating Expenses,2022-03-31 00:00:00,618980000.0,ADVENZYMES.NS
Depreciation And Amortization In Income Statement,2022-03-31 00:00:00,349830000.0,ADVENZYMES.NS
Amortization,2022-03-31 00:00:00,79980000.0,ADVENZYMES.NS
Depreciation Income Statement,2022-03-31 00:00:00,269850000.0,ADVENZYMES.NS
Research And Development,2022-03-31 00:00:00,6470000.0,ADVENZYMES.NS
Selling General And Administration,2022-03-31 00:00:00,354850000.0,ADVENZYMES.NS
Selling And Marketing Expense,2022-03-31 00:00:00,147660000.0,ADVENZYMES.NS
General And Administrative Expense,2022-03-31 00:00:00,207190000.0,ADVENZYMES.NS
Rent And Landing Fees,2022-03-31 00:00:00,42380000.0,ADVENZYMES.NS
Gross Profit,2022-03-31 00:00:00,4094740000.0,ADVENZYMES.NS
Cost Of Revenue,2022-03-31 00:00:00,1194300000.0,ADVENZYMES.NS
Total Revenue,2022-03-31 00:00:00,5289040000.0,ADVENZYMES.NS
Operating Revenue,2022-03-31 00:00:00,5289040000.0,ADVENZYMES.NS
Tax Effect Of Unusual Items,2021-03-31 00:00:00,,ADVENZYMES.NS
Tax Rate For Calcs,2021-03-31 00:00:00,,ADVENZYMES.NS
Normalized EBITDA,2021-03-31 00:00:00,,ADVENZYMES.NS
Total Unusual Items,2021-03-31 00:00:00,,ADVENZYMES.NS
Total Unusual Items Excluding Goodwill,2021-03-31 00:00:00,,ADVENZYMES.NS
Net Income From Continuing Operation Net Minority Interest,2021-03-31 00:00:00,,ADVENZYMES.NS
Reconciled Depreciation,2021-03-31 00:00:00,,ADVENZYMES.NS
Reconciled Cost Of Revenue,2021-03-31 00:00:00,,ADVENZYMES.NS
EBITDA,2021-03-31 00:00:00,,ADVENZYMES.NS
EBIT,2021-03-31 00:00:00,,ADVENZYMES.NS
Net Interest Income,2021-03-31 00:00:00,,ADVENZYMES.NS
Interest Expense,2021-03-31 00:00:00,,ADVENZYMES.NS
Interest Income,2021-03-31 00:00:00,5850000.0,ADVENZYMES.NS
Normalized Income,2021-03-31 00:00:00,,ADVENZYMES.NS
Net Income From Continuing And Discontinued Operation,2021-03-31 00:00:00,,ADVENZYMES.NS
Total Expenses,2021-03-31 00:00:00,,ADVENZYMES.NS
Rent Expense Supplemental,2021-03-31 00:00:00,21040000.0,ADVENZYMES.NS
Diluted Average Shares,2021-03-31 00:00:00,,ADVENZYMES.NS
Basic Average Shares,2021-03-31 00:00:00,,ADVENZYMES.NS
Diluted EPS,2021-03-31 00:00:00,,ADVENZYMES.NS
Basic EPS,2021-03-31 00:00:00,,ADVENZYMES.NS
Diluted NI Availto Com Stockholders,2021-03-31 00:00:00,,ADVENZYMES.NS
Net Income Common Stockholders,2021-03-31 00:00:00,,ADVENZYMES.NS
Otherunder Preferred Stock Dividend,2021-03-31 00:00:00,,ADVENZYMES.NS
Net Income,2021-03-31 00:00:00,,ADVENZYMES.NS
Minority Interests,2021-03-31 00:00:00,,ADVENZYMES.NS
Net Income Including Noncontrolling Interests,2021-03-31 00:00:00,,ADVENZYMES.NS
Net Income Continuous Operations,2021-03-31 00:00:00,,ADVENZYMES.NS
Tax Provision,2021-03-31 00:00:00,,ADVENZYMES.NS
Pretax Income,2021-03-31 00:00:00,,ADVENZYMES.NS
Other Non Operating Income Expenses,2021-03-31 00:00:00,,ADVENZYMES.NS
Special Income Charges,2021-03-31 00:00:00,,ADVENZYMES.NS
Other Special Charges,2021-03-31 00:00:00,-7250000.0,ADVENZYMES.NS
Write Off,2021-03-31 00:00:00,9300000.0,ADVENZYMES.NS
Impairment Of Capital Assets,2021-03-31 00:00:00,,ADVENZYMES.NS
Net Non Operating Interest Income Expense,2021-03-31 00:00:00,,ADVENZYMES.NS
Total Other Finance Cost,2021-03-31 00:00:00,9610000.0,ADVENZYMES.NS
Interest Expense Non Operating,2021-03-31 00:00:00,,ADVENZYMES.NS
Interest Income Non Operating,2021-03-31 00:00:00,5850000.0,ADVENZYMES.NS
Operating Income,2021-03-31 00:00:00,,ADVENZYMES.NS
Operating Expense,2021-03-31 00:00:00,,ADVENZYMES.NS
Other Operating Expenses,2021-03-31 00:00:00,,ADVENZYMES.NS
Depreciation And Amortization In Income Statement,2021-03-31 00:00:00,,ADVENZYMES.NS
Amortization,2021-03-31 00:00:00,64120000.0,ADVENZYMES.NS
Depreciation Income Statement,2021-03-31 00:00:00,,ADVENZYMES.NS
Research And Development,2021-03-31 00:00:00,6290000.0,ADVENZYMES.NS
Selling General And Administration,2021-03-31 00:00:00,243780000.0,ADVENZYMES.NS
Selling And Marketing Expense,2021-03-31 00:00:00,85500000.0,ADVENZYMES.NS
General And Administrative Expense,2021-03-31 00:00:00,158280000.0,ADVENZYMES.NS
Rent And Landing Fees,2021-03-31 00:00:00,21040000.0,ADVENZYMES.NS
Gross Profit,2021-03-31 00:00:00,,ADVENZYMES.NS
Cost Of Revenue,2021-03-31 00:00:00,,ADVENZYMES.NS
Total Revenue,2021-03-31 00:00:00,,ADVENZYMES.NS
Operating Revenue,2021-03-31 00:00:00,,ADVENZYMES.NS
